Analyze antibody-epitope interactions through HDX-MS or cryo-EM
Test binding kinetics under physiological conditions (BLI/SPR preferred over ELISA)
Use Rosetta-based CDR optimization (achieved 20-fold affinity improvement in SARS-CoV-2 RBD antibodies)
Validate with molecular dynamics simulations (>100ns production runs)
Process raw sequences with adaptive clustering thresholds:
| Parameter | Recommended Value | Rationale |
|---|---|---|
| CDR3 Length | ±3 aa from germline | Maintain structural flexibility |
| V-J Alignment | >85% identity | Preserve framework integrity |
| Performance Tier | Binding Affinity | Signal:Noise Ratio | Cross-Reactivity |
|---|---|---|---|
| Excellent | KD < 10 nM | ≥5:1 | None detected |
| Acceptable | KD 10-100 nM | ≥3:1 | <5% homologs |
| Poor | KD > 100 nM | <3:1 | Uncontrolled |
| Data synthesis from |
Key Limitations in Current Research:
No peer-reviewed validation data exists for SVR1-specific reagents in the provided literature
Epitope conservation analysis unavailable without structural data
Functional assays (neutralization/blocking) remain theoretical for this target
Researchers should: